AUPH News and Press, Aurinia Pharmaceuticals Inc From 01/03/23

Canada-based Aurinia Pharmaceuticals ( NASDAQ: AUPH ) on Tuesday said it had reached a settlement with India's Sun Pharmaceuticals ( OTCPK:SMPQY ) over its patent challenge of its lupus nephritis treatment Lupkynis. AUPH shares were 36.1% higher to $5.88 after the opening bell...

- Sun Pharmaceuticals and Aurinia agreed to file a joint motion to dismiss Inter Parties Review of Patent No. 10,286,036 - Parties have settled the patent infringement claim against Sun’s CEQUA® product - Settlements are Contingent Upon U.S. Patent Trial and Appeal Board (PTAB...

MHRA Approval follows European Commission marketing authorization of LUPKYNIS to treat adults with active lupus nephritis in 27 European Union Member States LUPKYNIS is the first oral medicine approved in the U.S. and Europe for the treatment of adults living with active lupus nephritis ...

Summary Aurinia has been facing many problems. Potential sales chatter may be a result of its problems. However, I see little reason for big pharma to buy AUPH. Aurinia’s ( AUPH ) price movement over the last 12 months seems predicated on 3 things - key ma...

Aurinia Pharmaceuticals Inc. (AUPH) Q3 2022 Earnings Conference Call November 03, 2022 08:30 AM ET Company Participants Peter Greenleaf - President & Chief Executive Officer Joe Miller - Chief Financial Officer Conference Call Participants Ed Arce - H...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH ) stock are down 30% today after the company reported its latest financial results and lowered its forward guidance. AUPH stock is one of the top trending tickers on S...

Canadian biotech Aurinia Pharmaceuticals ( NASDAQ: AUPH ) lost ~22% pre-market Thursday even after announcing better-than-expected financials for Q3 2022 as the company lowered its full-year guidance citing weak demand for lupus nephritis therapy Lupkynis. “Un...

Aurinia Pharma press release ( NASDAQ: AUPH ): Q3 GAAP EPS of -$0.06 beats by $0.13 . Revenue of $55.78M (+280.5% Y/Y) beats by $19.38M . “During the third quarter, we demonstrated progress across many key commercial metrics for LUPKYNIS, including an in...

Net revenue of $55.8 million for Q3 2022; including $30.0 million milestone from Otsuka related to European Approval of LUPKYNIS ® (voclosporin) Adjusts net product revenue guidance to $100-105 million from sales of LUPKYNIS for 2022 Issues preliminary net...

Aurinia Pharma ( NASDAQ: AUPH ) is scheduled to announce Q3 earnings results on Thursday, November 3rd, before market open. The consensus EPS Estimate is -$0.19 (+51.3% Y/Y) and the consensus Revenue Estimate is $36.4M (+148.3% Y/Y). Over the last 1 year, AUPH has be...